Tselekoksib

General characteristics. Structure:

Active ingredient: 100 mg or 200 mg of a tselekoksib.

Pharmacological properties:

Pharmacodynamics. Has antiinflammatory, febrifugal and analgeziruyushchy effect, slows down aggregation of thrombocytes. Oppressing cyclooxygenase-2, reduces amount of prostaglandins (preferential in the inflammation center), suppresses exudative and proliferative phases of an inflammation.

Indications to use:

- Pseudorheumatism;

- reactive synovitis;

- osteoarthrosis;

- ankylosing spondylarthritis;

- a joint syndrome at an exacerbation of gout;

- psoriasis arthritis.

Route of administration and doses:

Drug is accepted inside. The adult appoint 200 mg/days divided into 1-2 receptions, if necessary increase a daily dose to 400 mg.

Features of use:

During treatment control of a picture of peripheral blood and a functional condition of a liver and kidneys is necessary. In need of definition of 17 ketosteroids treatment should be cancelled for 48 h prior to a research.

Influence on ability to control of motor transport and potentially dangerous mechanisms: during treatment it is necessary to avoid occupations potentially dangerous types of activity demanding the increased speed of psychomotor reactions and concentration of attention.

Side effects:

From the alimentary system: NPVS-gastropathy, abdominal pain, nausea, vomiting, heartburn, loss of appetite, diarrhea; at prolonged use in high doses - an ulceration of a mucous membrane of a GIT, gastrointestinal bleeding, an odontorrhagia, an abnormal liver function (increase in activity of "hepatic" transferases).

From a nervous system: headache, dizziness, drowsiness or sleeplessness, depression, excitement.

From sense bodys: decrease in hearing, sonitus.

From cardiovascular system: increase in arterial pressure, tachycardia.

From respiratory system: decrease in resistance to respiratory infections (sinusitis, rhinitis, pharyngitis), pharyngalgia, cough, short wind, bronchospasm.

From an urinary system: renal failure, edematous syndrome.

From bodies of a hemopoiesis: agranulocytosis, leukopenia, anemia, thrombocytopenia. Allergic reactions: skin rash, itch, small tortoiseshell, photosensitization, Quincke's disease.

Others: an alopecia, the increased sweating, uterine and hemorrhoidal bleeding.

Interaction with other medicines:

Reduces efficiency of uricosuric medicines, strengthens effect of anticoagulants, antiagregant, fibrinolitik; side effects of glucocorticosteroids, mineralokortikoid and estrogen; reduces efficiency of hypotensive medicines and diuretics; increases hypoglycemic action of derivatives of sulphonylurea.

Reduces efficiency of APF inhibitors, increases risk of developing of a renal failure.

Flukonazol (CYP2C9 inhibitor) increases concentration of a tselikoksib in blood and risk of development of side effects. Antacids and Colestyraminum reduce absorption.

Increases concentration in blood of the drugs Li+, a methotrexate.

Myelotoxic medicines strengthen manifestations of a gematotoksichnost of drug.

Contraindications:

Hypersensitivity, allergic reactions to acetylsalicylic acid, etc. non-steroidal anti-inflammatory drugs, sulfonamide - the containing medicines, a full or incomplete combination of bronchial asthma, the nose recuring a polypose and okolonosovy bosoms and intolerance of acetylsalicylic acid or other NPVS (including in the anamnesis), a round ulcer in stages of an aggravation or bleeding from a GIT, colitis, chronic heart failure (the II-IV Art. on NYHA), the operation of aortocoronary shunting, an ischemic heart disease which is (clinically confirmed), diseases of peripheral arteries and the expressed cerebrovascular diseases, a heavy liver/renal failure, pregnancy, the lactation period, children's age (up to 18 years).

With care apply at patients with a peptic ulcer of a stomach and a 12-perstny gut (including in the anamnesis), gastrointestinal bleeding in the anamnesis; at a concomitant use of warfarin, etc. anticoagulants, CYP2C9 inhibitors; at hypostases, a liquid delay, at patients with a liver failure of moderate severity, diseases of cardiovascular system.

Issue conditions:

According to the recipe

Packaging:

Mg capsules 100 or 200 in a blister strip packaging No. 10.